JP6053675B2 - 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６ - Google Patents

抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６ Download PDF

Info

Publication number
JP6053675B2
JP6053675B2 JP2013515556A JP2013515556A JP6053675B2 JP 6053675 B2 JP6053675 B2 JP 6053675B2 JP 2013515556 A JP2013515556 A JP 2013515556A JP 2013515556 A JP2013515556 A JP 2013515556A JP 6053675 B2 JP6053675 B2 JP 6053675B2
Authority
JP
Japan
Prior art keywords
pla2g16
cell
virus
cells
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013515556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537515A (ja
JP2013537515A5 (https=
Inventor
ブルメルカンプ，テイン・エル
カレッテ，ヤン・エー
Original Assignee
ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ filed Critical ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ
Publication of JP2013537515A publication Critical patent/JP2013537515A/ja
Publication of JP2013537515A5 publication Critical patent/JP2013537515A5/ja
Application granted granted Critical
Publication of JP6053675B2 publication Critical patent/JP6053675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/1036—Measuring load distribution, e.g. podologic studies
    • A61B5/1038—Measuring plantar pressure during gait
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/112—Gait analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6802—Sensor mounted on worn items
    • A61B5/6804—Garments; Clothes
    • A61B5/6807—Footwear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7225—Details of analogue processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7278—Artificial waveform generation or derivation, e.g. synthesizing signals from measured signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7285—Specific aspects of physiological measurement analysis for synchronizing or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Signal Processing (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Toxicology (AREA)
JP2013515556A 2010-06-18 2011-06-17 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６ Expired - Fee Related JP6053675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35642610P 2010-06-18 2010-06-18
US61/356,426 2010-06-18
PCT/US2011/040920 WO2011160043A2 (en) 2010-06-18 2011-06-17 Pla2g16 as a target for antiviral compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016153821A Division JP6285993B2 (ja) 2010-06-18 2016-08-04 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６

Publications (3)

Publication Number Publication Date
JP2013537515A JP2013537515A (ja) 2013-10-03
JP2013537515A5 JP2013537515A5 (https=) 2014-07-31
JP6053675B2 true JP6053675B2 (ja) 2016-12-27

Family

ID=45348904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013515556A Expired - Fee Related JP6053675B2 (ja) 2010-06-18 2011-06-17 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６
JP2016153821A Expired - Fee Related JP6285993B2 (ja) 2010-06-18 2016-08-04 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016153821A Expired - Fee Related JP6285993B2 (ja) 2010-06-18 2016-08-04 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６

Country Status (8)

Country Link
US (2) US20130211209A1 (https=)
EP (1) EP2583099B1 (https=)
JP (2) JP6053675B2 (https=)
KR (1) KR101931628B1 (https=)
AU (1) AU2011268127B2 (https=)
CA (1) CA2805409A1 (https=)
ES (1) ES2611150T3 (https=)
WO (1) WO2011160043A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015018797A2 (en) * 2013-08-05 2015-02-12 Haplogen Gmbh Antiviral compounds
GB2527364A (en) * 2014-06-20 2015-12-23 Imp Innovations Ltd Treatment
WO2018050631A1 (en) 2016-09-13 2018-03-22 Haplogen Gmbh Antiviral compounds
WO2019068841A1 (en) 2017-10-05 2019-04-11 Haplogen Gmbh ANTIVIRAL COMPOUNDS
EP3989971A4 (en) * 2019-06-28 2023-08-09 Niklovir AB NEW ANTIVIRAL THERAPIES
EP4045920A4 (en) * 2019-10-15 2023-10-11 Jnana Therapeutics Inc. INTERACTION DISCOVERY PLATFORM WITH A REACTIVE AFFINITY PROBE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
TW577875B (en) 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
US6518424B1 (en) 1998-11-12 2003-02-11 Elan Pharmaceuticals, Inc. Substituted pyrimidine compositions and methods of use
EP1686119B1 (en) 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GT200600228A (es) 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
CN101291666A (zh) 2005-08-17 2008-10-22 加利福尼亚大学董事会 新系列的磷脂酶a2抑制剂对痛觉过敏和脊髓pge2释放的全身和鞘内效应
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
JP5366074B2 (ja) * 2008-11-05 2013-12-11 プライムテック株式会社 共通サイトカイン受容体γ鎖遺伝子ノックアウトブタ
WO2011006145A2 (en) 2009-07-09 2011-01-13 Whitehead Institute For Biomedical Research Compositions and methods for mammalian genetics and uses thereof

Also Published As

Publication number Publication date
KR101931628B1 (ko) 2019-03-13
EP2583099B1 (en) 2016-11-02
ES2611150T3 (es) 2017-05-05
JP2013537515A (ja) 2013-10-03
AU2011268127A1 (en) 2013-01-10
US20130211209A1 (en) 2013-08-15
KR20140004556A (ko) 2014-01-13
EP2583099A2 (en) 2013-04-24
CA2805409A1 (en) 2011-12-22
JP6285993B2 (ja) 2018-02-28
US20130219533A1 (en) 2013-08-22
AU2011268127B2 (en) 2016-01-14
WO2011160043A2 (en) 2011-12-22
WO2011160043A3 (en) 2012-05-31
US9011821B2 (en) 2015-04-21
JP2017018113A (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
JP6285993B2 (ja) 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６
Gu et al. Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2
Uzureau et al. APOL1 C-terminal variants may trigger kidney disease through interference with APOL3 control of actomyosin
Das et al. Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding
Xu et al. PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection
US20150065556A1 (en) Therapeutic targets for mitochondrial disorders
Sung et al. The 8ab protein of SARS-CoV is a luminal ER membrane-associated protein and induces the activation of ATF6
Madu et al. Heparan sulfate is a selective attachment factor for the avian coronavirus infectious bronchitis virus Beaudette
van Vliet et al. Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site
Jackel-Cram et al. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase–Akt-2 pathway
US11267874B2 (en) Sensor systems for target ligands and uses thereof
Tse et al. A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus
Zhao et al. Myeloid neddylation targets IRF7 and promotes host innate immunity against RNA viruses
Fukuma et al. Inability of rat DPP4 to allow MERS-CoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein
Dolskiy et al. The tissue distribution of SARS-CoV-2 in transgenic mice with inducible ubiquitous expression of hACE2
JP2012532615A (ja) 哺乳動物遺伝学のための組成物および方法、ならびにその使用
Desmarets et al. A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells
Kong et al. Gene-teratogen interactions influence the penetrance of birth defects by altering Hedgehog signaling strength
Wang et al. Inhibition of lysosome-tethered Ragulator-Rag-3D complex restricts the replication of Enterovirus 71 and Coxsackie A16
Yao et al. Characterization of key spike RBD residues influencing SARS-CoV-2 variant adaptation to avian ACE2
Fan et al. Coxsackievirus Protease 2A Targets Host Protease ATG4A to Impair Autophagy
Ma et al. Glycosylphosphatidylinositol biosynthesis functions as a conserved host defense pathway against coronaviruses via regulation of LY6E
Shi et al. Genome-scale CRISPR screen identifies TMEM198 driving double membrane vesicle formation in swine alphacoronavirus and murine betacoronavirus infected cells
Olson et al. Development of a replication competent murine norovirus reporter system
Ham et al. The SpACE-CCM: A facile and versatile cell culture medium-based biosensor for detection of SARS-CoV-2 spike-ACE2 interaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161129

R150 Certificate of patent or registration of utility model

Ref document number: 6053675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees